Review Finds Low Bleeding Risk With Tyrosine Kinase Inhibitor–Anticoagulant Combinations in CML

Key Clinical Takeaways: 

• A systematic review found few major bleeding or thrombotic events among patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs) with anticoagulants.
• Most serious bleeding events occurred in patients with additional risk factors, including renal impairment, advanced disease, advanced age, or polypharmacy.
• Investigators propose a chronic myeloid leukemia–specific bleeding assessment tool to guide anticoagulant selection and risk stratification.

Limited Evidence Suggests Favorable Safety Profile

A systematic review suggests that combining TKIs with anticoagulant therapy is generally safe for patients with chronic myeloid leukemia, although investigators recommend individualized risk assessment for patients with additional bleeding risk factors.

The review evaluated pharmacokinetic studies, case reports, and retrospective observational studies examining the safety of combining TKIs with direct oral anticoagulants (DOACs), warfarin, low-molecular-weight heparin, and other anticoagulants in patients with CML.

According to the authors, this represents the first systematic review focused specifically on anticoagulant use in patients receiving TKIs for CML.

Pharmacokinetic Studies Found No Major Safety Concerns

Two randomized pharmacokinetic studies evaluated potential drug interactions in healthy volunteers.

One study assessed bosutinib administered with dabigatran and found no major bleeding or thromboembolic events. Gastrointestinal adverse events, primarily diarrhea and nausea, were the most frequently reported toxicities. Pharmacokinetic analyses demonstrated similar dabigatran exposure whether administered alone or with bosutinib.

A second study evaluated nilotinib with warfarin. Investigators observed no meaningful pharmacokinetic interactions and no thrombotic or bleeding events.

However, adverse events including headache, nausea, vomiting, somnolence, and hot flashes occurred in most participants, and 2 individuals discontinued treatment because of ventricular arrhythmia or a local inflammatory reaction.

Serious Bleeding Events Were Uncommon

Across 8 published case reports and 3 retrospective observational studies, investigators found no newly reported thrombotic events associated with TKI-anticoagulant combinations.

Most case reports described successful use of apixaban, rivaroxaban, warfarin, enoxaparin, or heparin without major bleeding complications.

Only 2 serious bleeding events were identified.

One patient with CML in blast crisis developed gastrointestinal bleeding related to disseminated intravascular coagulation while receiving imatinib and prophylactic danaparoid. Another elderly patient receiving bosutinib, warfarin, aspirin, and several interacting medications experienced pulmonary hemorrhage associated with a markedly elevated international normalized ratio shortly after initiating bosutinib.

Among retrospective studies, investigators reported 2 intramuscular hematomas in patients receiving imatinib with edoxaban, along with isolated cases of renal impairment requiring anticoagulant dose adjustment or discontinuation.

Risk Factors May Guide Anticoagulant Selection

The review found that major bleeding events primarily occurred among patients with renal dysfunction, advanced-stage CML, advanced age, polypharmacy, or critical illness.

The authors suggest that these patient-specific characteristics should inform anticoagulant selection and monitoring.

Among available DOACs, apixaban demonstrated the most favorable safety profile based on available evidence and was identified as the preferred oral anticoagulant for standard-risk patients.

Low-molecular-weight heparin was also considered a reasonable option because of its predictable pharmacokinetics and limited potential for drug-drug interactions.

Proposed Bleeding Assessment Tool

Recognizing that existing bleeding prediction models have not been validated for patients with CML, investigators proposed a disease-specific Bleeding Assessment Tool for Chronic Myeloid Leukemia (BAT-CML).

The proposed framework incorporates disease stage, renal function, concomitant medications, and other clinical factors to better estimate bleeding risk in patients receiving both TKIs and anticoagulants.

The authors recommend baseline assessment of creatinine clearance, consideration of DOAC drug-level monitoring when available, and individualized anticoagulant selection for higher-risk patients.

Implications for Managed Care

For managed care organizations, the findings support individualized anticoagulation strategies rather than avoidance of anticoagulant therapy in patients receiving TKIs.

Although available evidence suggests that TKI-anticoagulant combinations can generally be used safely, the authors emphasize the need for careful assessment of patient-specific risk factors and ongoing monitoring for bleeding complications.

Prospective randomized trials remain necessary to better define optimal anticoagulant selection, validate the proposed BAT-CML tool, and clarify long-term safety outcomes.

Conclusion

Current evidence suggests that anticoagulant therapy can generally be administered safely alongside TKIs in patients with CML, particularly among standard-risk individuals. The authors conclude that individualized bleeding risk assessment and prospective validation of CML-specific management tools are needed to further optimize treatment decisions.

Reference

Gameil A, Ghasoub R, Jafari N, et al. Evaluating the safety of combining tyrosine kinase inhibitors with anticoagulants in chronic myeloid leukemia: a systematic review. Oncology. 2026;104(8): 900–913. doi:10.1159/000550346